Department of Translational Neuroscience, Wake Forest School of Medicine, Winston-Salem, NC 27101.
Department of Psychiatry, Icahn School of Medicine at Mount Sinai, NewYork, NY 10029.
eNeuro. 2024 Feb 15;11(2). doi: 10.1523/ENEURO.0388-23.2023. Print 2024 Feb.
Opioid use disorder (OUD) is a public health crisis currently being exacerbated by increased rates of use and overdose of synthetic opioids, primarily fentanyl. Therefore, the identification of novel biomarkers and treatment strategies to reduce problematic fentanyl use and relapse to fentanyl taking is critical. In recent years, there has been a growing body of work demonstrating that the gut microbiome can serve as a potent modulator of the behavioral and transcriptional responses to both stimulants and opioids. Here, we advance this work to define how manipulations of the microbiome drive fentanyl intake and fentanyl-seeking in a translationally relevant drug self-administration model. Depletion of the microbiome of male rats with broad spectrum antibiotics leads to increased drug administration on increased fixed ratio, progressive ratio, and drug seeking after abstinence. Utilizing 16S sequencing of microbiome contents from these animals, specific populations of bacteria from the gut microbiome correlate closely with levels of drug taking. Additionally, global proteomic analysis of the nucleus accumbens following microbiome manipulation and fentanyl administration to define how microbiome status alters the functional proteomic landscape in this key limbic substructure. These data demonstrate that an altered microbiome leads to marked changes in the synaptic proteome in response to repeated fentanyl treatment. Finally, behavioral effects of microbiome depletion are reversible by upplementation of the microbiome derived short-chain fatty acid metabolites. Taken together, these findings establish clear relevance for gut-brain signaling in models of OUD and lay foundations for further translational work in this space.
阿片类药物使用障碍(OUD)是目前公共卫生危机的主要问题,其原因是阿片类药物的使用和过量使用,尤其是合成阿片类药物芬太尼的情况日益加剧。因此,确定减少芬太尼使用问题和复吸芬太尼的新型生物标志物和治疗策略至关重要。近年来,越来越多的研究表明,肠道微生物组可以作为一种强大的调节剂,调节对兴奋剂和阿片类药物的行为和转录反应。在这里,我们将这项工作推进到定义肠道微生物组如何在转化相关的药物自我给药模型中驱动芬太尼摄入和芬太尼觅药。广谱抗生素对雄性大鼠的微生物组进行耗竭会导致在增加固定比率、递增比率和戒断后觅药时增加药物给药。利用这些动物的微生物组内容物的 16S 测序,肠道微生物组中的特定细菌种群与药物摄入量密切相关。此外,对微生物组操作和芬太尼给药后的伏隔核进行全蛋白质组分析,以定义微生物组状态如何改变该关键边缘亚结构中的功能蛋白质组图谱。这些数据表明,改变的微生物组会导致重复芬太尼治疗后突触蛋白质组发生明显变化。最后,微生物组耗竭的行为效应可以通过补充微生物组衍生的短链脂肪酸代谢物来逆转。总之,这些发现为 OUD 模型中的肠道-大脑信号传递确立了明确的相关性,并为该领域的进一步转化工作奠定了基础。